Solventum (NYSE: SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership ...

Solventum detailed its 2025-2028 growth strategy, reaffirmed its 2025 guidance, and reported Q4 earnings that topped expectations with strong sales and EPS.

Shares of Solventum Corp. SOLV shed 2.25% to $75.89 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,572.07 ...

Shares of NYSE:SOLV opened at $77.96 on Wednesday. The business has a 50 day moving average price of $73.65 and a 200 day moving average price of $70.55. Solventum has a twelve month low of $47.16 ...

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports.

I would like to welcome everyone to Solventum's Fourth Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise.

Diversified healthcare company Solventum (NYSE:SOLV) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at ...

SOLVENTUM ($SOLV) posted quarterly earnings results on Thursday, February 27th. The company reported earnings of $1.41 per share, beating estimates of $1.35 by $0.06 ...